A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Phase 3
18+
29 sites in AR, CA, FL +15
What this study is about
This Phase 3 study is testing Lurbinectedin in people with lung cancer. The primary outcome being measured is Number of Participants With Objective Response Rate Assessed by Blinded Independent Central Review.
Simplified from trial records by PatientMatch.
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
lurbinectedin, topotecan
injection, intravenous, oral (Oral Capsule)
Primary: Number of Participants With Objective Response Rate Assessed by Blinded Independent Central Review, Overall Survival
Secondary: Change from Baseline in The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-C30, Change from Baseline in The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer 29 (EORTC QLQ-LC29), Disease Control Rate As Assessed by Blinded Independent Central Review and Investigator, Duration of Response As Assessed by Blinded Independent Central Review and Investigator, Number of Participants With Objective Response Rate Assessed by Investigator, Overall Number of Participants With Treatment-emergent Adverse Events Following I-DXd Monotherapy, Pharmacokinetic Parameter Area Under the Plasma Concentration-Time Curve for I-DXd, Total Anti-B7-H3 Antibody, and MAAA-1181a, Pharmacokinetic Parameter Maximum Concentration for I-DXd, Total Anti-B7-H3 Antibody, and MAAA-1181a
Oncology